Prostate Cancer Stages: What Each Stage Means

Hearing the words “prostate cancer” is unsettling enough without also trying to make sense of stage numbers, Gleason scores, and letters like T, N, and M on a pathology report. Prostate cancer stages describe how far the cancer has spread and how aggressive it looks under the microscope, and that combination is what guides almost every treatment decision that follows. Here’s a plain-language walk-through of how staging works, what each stage generally means, and the questions worth asking your doctor once you have your own numbers in hand.

Why Staging Matters

Staging exists to answer one practical question: how much cancer is in the body, and where is it? That single piece of information shapes nearly everything that follows — whether active surveillance is a reasonable option, whether surgery or radiation is likely to be curative, whether hormone therapy should be part of the plan, and how often follow-up testing should happen. Two men with a prostate cancer diagnosis can have very different outlooks and very different treatment plans depending entirely on their stage, which is why doctors invest real time in determining it accurately before recommending a course of treatment.

The TNM System, Explained

Prostate cancer staging in the United States follows the American Joint Committee on Cancer’s TNM system, most recently updated in 2018. Each letter captures a different dimension of the cancer:

• T (Tumor). Describes the size and extent of the main tumor within and around the prostate. A “clinical T” (cT) stage is estimated from a physical exam, biopsy results, and imaging; a “pathological T” (pT) stage comes from examining tissue removed during surgery and is generally considered more accurate, since it’s based on direct examination rather than estimation.
• N (Nodes). Describes whether cancer has spread to nearby lymph nodes. N0 means no spread to nearby nodes; N1 means it has.
• M (Metastasis). Describes whether cancer has spread to distant parts of the body, such as bones, the liver, or lymph nodes far from the prostate. M0 means no distant spread; M1 means it has, sometimes broken down further by location.

As a general rule, a lower number after each letter means less extent of disease. These three categories are then combined with PSA level and Grade Group to arrive at an overall stage, written as a Roman numeral from I to IV.

Gleason Score and Grade Groups

Alongside the TNM categories, your pathology report will include a Gleason score and a corresponding Grade Group, both of which describe how abnormal the cancer cells look under a microscope and how likely the cancer is to grow and spread quickly. This is sometimes confused with staging, but it’s a separate measure: staging describes where the cancer is, while grading describes how aggressive it looks. The Grade Group system, which has largely replaced talking about the raw Gleason score alone, groups results into five categories:

• Grade Group 1 corresponds to a Gleason score of 6 or less — the least aggressive-appearing cancer.
• Grade Group 2 corresponds to a Gleason score of 3+4=7, where the more common pattern seen is the less aggressive one.
• Grade Groups 3 and 4 correspond to a Gleason score of 4+3=7, or a Gleason score of 8, where the more aggressive pattern is more prominent.
• Grade Group 5 corresponds to a Gleason score of 9 or 10 — the most aggressive-appearing cancer.

A higher Grade Group generally means the cancer is more likely to grow and spread without treatment, and it plays a significant role in overall staging and in treatment decisions, including whether active surveillance is a reasonable option.

Stage I: Small and Confined

Stage I prostate cancer describes a tumor that’s small, confined to the prostate (clinical stage T1 or T2a, or pathological stage T2), has a Grade Group of 1, and a PSA under 10. This is the earliest, most favorable stage, and it’s often associated with slow-growing disease that may be a reasonable candidate for active surveillance — close monitoring without immediate treatment — rather than surgery or radiation right away, depending on individual factors your doctor will discuss with you.

Stage II: Still Localized, More to Consider

Stage II is divided into three sub-stages — IIA, IIB, and IIC — all of which still describe cancer that hasn’t spread beyond the prostate or to nearby lymph nodes. What changes between them is Grade Group and PSA: IIA still involves Grade Group 1 disease, IIB involves Grade Group 2 with PSA under 20, and IIC involves Grade Group 3 or 4 with PSA under 20. In practical terms, Stage II still represents localized disease, but the higher sub-stages reflect either a somewhat more aggressive cell pattern or a higher PSA than Stage I, both of which factor into whether active surveillance remains reasonable or whether more active treatment is recommended.

Stage III: Local Spread or Higher-Grade Disease

Stage III also has three sub-stages. IIIA involves T1 or T2 tumors with any Grade Group from 1 to 4, but a PSA of 20 or higher. IIIB involves a tumor that has grown into nearby tissue such as the seminal vesicles (T3 or T4), with Grade Groups 1 through 4 and any PSA level. IIIC involves any T stage with Grade Group 5 — the most aggressive grade — regardless of PSA. In short, Stage III captures cancer that’s either grown beyond the prostate into nearby structures, has a notably elevated PSA, or looks highly aggressive under the microscope, even if it technically hasn’t spread to lymph nodes or distant sites yet.

Stage IV: Spread Beyond the Prostate Area

Stage IV is split into two sub-stages based on where the cancer has spread. Stage IVA means the cancer has reached nearby lymph nodes (N1) but hasn’t spread to distant sites (M0). Stage IVB means the cancer has spread to distant locations — distant lymph nodes, bones, or other organs (M1) — which is sometimes referred to as metastatic prostate cancer. Treatment at this stage usually shifts toward systemic approaches like hormone therapy, sometimes combined with chemotherapy or newer targeted medications, aimed at controlling the cancer and managing symptoms over the long term, since a cure becomes less likely once distant spread has occurred, though many men live for years with well-managed metastatic disease.

Risk Groups: A Related but Separate Tool

If your prostate cancer hasn’t spread, your doctor may also assign it to a risk group — separate from the numbered stage — as an additional way to help guide treatment decisions and estimate how likely the cancer is to come back after treatment. Risk groups combine stage, PSA, and Grade Group information in a slightly different way than the overall stage number does, and your doctor can walk you through where your specific case falls and what it means for your options.

How Staging Affects Your Treatment Options

Generally speaking, lower-stage, lower-grade prostate cancer opens the door to a wider range of reasonable choices, including active surveillance for carefully selected cases, where the cancer is monitored closely with regular PSA testing, exams, and follow-up biopsies rather than treated right away. As stage or grade increases, treatment more often shifts toward surgery (radical prostatectomy), radiation therapy, or a combination of local treatment with hormone therapy. For cancer that has spread beyond the prostate and nearby tissue, systemic treatments like hormone therapy typically become the backbone of the treatment plan, sometimes alongside radiation to specific symptomatic areas. Every case is individual, and your own stage, grade, PSA trend, age, overall health, and personal preferences all factor into the specific plan your doctor recommends.

How Doctors Determine Your Stage

Arriving at a stage usually involves pulling together several pieces of information rather than a single test. Your PSA blood test and a digital rectal exam provide an initial sense of extent. A prostate biopsy, examined by a pathologist, supplies the Gleason score and Grade Group. For higher-risk cases — a higher Grade Group, a notably elevated PSA, or symptoms suggesting possible spread — your doctor may order imaging such as a CT scan, MRI, bone scan, or a newer PSMA PET scan to check for cancer in lymph nodes, bones, or other organs before finalizing the stage. Not everyone needs every test; your doctor will decide which imaging makes sense based on your initial PSA, Grade Group, and clinical exam findings, since imaging carries its own cost and isn’t necessary for every diagnosis, particularly lower-risk, clearly localized cases.

Questions Worth Asking Your Doctor

• What is my exact stage and Grade Group, and what does that combination mean for my specific case?
• Is my cancer a reasonable candidate for active surveillance, or does it need treatment now?
• How was my stage determined — clinical findings, imaging, or pathology from a prior procedure?
• What would change my stage or risk group if it were reassessed later?
• What’s the realistic goal of treatment at my stage — cure, long-term control, or symptom management?

Frequently Asked Questions

Is Stage I prostate cancer curable?

Stage I prostate cancer is generally associated with a favorable outlook, and many men are successfully treated or safely monitored through active surveillance without the cancer progressing. Your doctor can give you a more individualized sense of outlook based on your specific case.

What’s the difference between staging and grading?

Staging (the TNM system and overall stage number) describes where the cancer is and how far it has spread. Grading (the Gleason score and Grade Group) describes how aggressive the cancer cells look under a microscope. Both are used together to guide treatment decisions.

Can my prostate cancer stage change over time?

The stage assigned at diagnosis generally doesn’t change, since it reflects the disease at that point in time, but your doctor may use terms like “recurrent” or discuss a new assessment if the cancer progresses or returns after treatment. Active surveillance involves regularly reassessing the cancer, which can lead to a change in treatment approach even if the original stage label stays the same.

Does a higher PSA always mean a higher stage?

Not necessarily on its own. PSA is one factor among several — including tumor extent, lymph node involvement, and Grade Group — used together to determine overall stage. A high PSA can have multiple causes, and your doctor will interpret it alongside your other results.

What does “metastatic prostate cancer” mean?

It means the cancer has spread beyond the prostate and nearby tissue to distant parts of the body, such as bones or distant lymph nodes — corresponding to Stage IVB. Treatment at this stage generally focuses on systemic therapies like hormone therapy to control the cancer over the long term.

This article is for general educational purposes and isn’t a substitute for personalized medical advice. Staging is complex and individualized — always discuss your specific pathology report and stage with your own doctor.

Prostate cancer staging can feel like a wall of unfamiliar letters and numbers at first, but it boils down to two related questions: how far has the cancer spread, and how aggressive does it look? Together, the TNM categories, PSA level, and Grade Group answer both, and that combination is what your doctor uses to recommend a plan suited to your specific situation. If you’ve just received a diagnosis, it’s entirely reasonable to ask your doctor to walk through your own stage and Grade Group in plain language — and to write down the answer, since there’s a lot to take in during that first conversation.